Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial-Reference-Cited by-同舟云学术

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

Published:2020-08 Issue:8 Volume:7 Page:e533-e544
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Bollen Pauline D J,Moore Cecilia L,Mujuru Hilda A,Makumbi Shafic,Kekitiinwa Adeodata R,Kaudha Elisabeth,Parker Anna,Musoro Godfrey,Nanduudu Annet,Lugemwa Abbas,Amuge Pauline,Hakim James G,Rojo Pablo,Giaquinto Carlo,Colbers Angela,Gibb Diana M,Ford Deborah,Turkova Anna,Burger David M

Funder

Medical Research Council

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference21 articles.

1. HIV drug resistance in low-income and middle-income countries;Hamers;Lancet HIV,2018

2. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study;Cahn;Lancet,2013

3. Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action;Penazzato;Lancet HIV,2018

4. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: forty-eight-week results from IMPAACT P1093;Viani;Pediatr Infect Dis J,2015

5. Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: results of the IMPAACT P1093 study;Viani;J Pediatric Infect Dis Soc,2020

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study;Biomedicines;2024-09-12

2. Influence of age and co‐medication on dolutegravir glucuronidation in paediatric patients;British Journal of Clinical Pharmacology;2024-09-03

3. Identification and simultaneous quantification of potential genotoxic impurities in first-line HIV drug dolutegravir sodium using fast ultrasonication-assisted extraction method coupled with GC–MS and in-silico toxicity assessment;Journal of Chromatography B;2024-09

4. Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1;Infectious Diseases and Therapy;2024-07-04

5. Disparities in access to Dolutegravir in West African children, adolescents and young adults aged 0-24 years living with HIV. A IeDEA Pediatric West African cohort analysis;2024-05-25